4.8 Article

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer

期刊

THERANOSTICS
卷 11, 期 13, 页码 6632-6643

出版社

IVYSPRING INT PUBL
DOI: 10.7150/thno.57706

关键词

cancer stem cells; metastasis; EGFR; circulating tumor cells; CTC cluster; circulating cancer stem cell

资金

  1. Department of Defense [W81XWH-16-1-0021, W81XWH-20-1-0679]
  2. NIH [R00CA160638, R01CA245699, T32 CA009560, T32 CA080621-15, T32GM008061]
  3. Susan G. Komen Foundation [CCR18548501]
  4. American Cancer Society [ACS127951-RSG-15-025-01-CSM]
  5. Northwestern University

向作者/读者索取更多资源

Research has shown that inhibiting EGFR can block the circulating cancer stem cell (cCSC) clustering and lung metastasis of triple-negative breast cancer (TNBC). In addition to CD44, microRNA-30c also plays a negative regulatory role in cCSC clustering and lung metastasis.
Triple-negative breast cancer (TNBC) is one of the most aggressive and metastatic breast cancer subtypes lacking targeted therapy. Our recent work demonstrated that circulating tumor cell (CTC) clusters and polyclonal metastasis of TNBC are driven by aggregation of CD44(+) cancer stem cells (CSC) and associated with an unfavorable prognosis, such as low overall survival. However, there is no existing therapeutic that can specifically block CTC or CSC cluster formation. Methods: Using patient-derived xenograft (PDX) models, we established an ex vivo tumor cell clustering assay for a pilot screening of blockade antibodies. After identifying EGFR as a target candidate, we modulated the gene expression and inhibited its kinase activity to determine its functional importance in tumor cell clustering and therapeutic inhibition of lung metastasis. We also examined the molecular regulation network of EGFR and a potential connection to CSC marker CD44 and microRNAs, which regulate CTC clustering. Results: We report here that EGFR inhibition successfully blocks circulating CSC (cCSC) clustering and lung metastasis of TNBC. EGFR enhances CD44-mediated tumor cell aggregation and CD44 stabilizes EGFR. Importantly, blocking EGFR by a novel anti-EGFR monoclonal antibody (clone LA1) effectively blocked cell aggregation in vitro and reduced lung metastasis in vivo. Furthermore, our data demonstrated that the tumor suppressor microRNA-30c serves as another negative regulator of cCSC clustering and lung metastasis by targeting CD44 as well as its downstream effector EGFR. Conclusion: Our studies identify a novel anti-EGFR therapeutic strategy to inhibit cCSC aggregation and therefore abolish cCSC cluster-mediated metastasis of TNBC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据